Gilead Sciences (GILD) Change in Receivables (2009 - 2026)
Gilead Sciences' (GILD) quarterly Change in Receivables came in at -$134.0 million in Q1 2026, down 69.62% YoY from -$441.1 million in Q1 2025, and up 25.14% on a QoQ basis from -$179.0 million in Q4 2025.
Gilead Sciences (GILD) Change in Receivables (2009 - 2026) Analysis & Trends
Gilead Sciences (GILD) has 18 years of Change in Receivables data on file, last reported at -$134.0 million in Q1 2026.
- Quarterly Change in Receivables fell 69.62% year-over-year to -$134.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $312.0 million (up 209.86% YoY) and the FY2025 annual result came in at $367.0 million, up 364.03% from the prior year.
- Change in Receivables climbed to -$134.0 million in Q1 2026, from -$179.0 million in the prior quarter.
- In the past five years, Change in Receivables ranged from a high of $612.0 million in Q3 2023 to a low of -$699.0 million in Q1 2022.
- A 5-year average of $20.2 million and a median of $29.0 million in 2024 frame the typical range for Change in Receivables.
- The widest YoY moves for Change in Receivables: up 906.9% in 2025, down 219.7% in 2025.
- Tracing GILD's Change in Receivables over 5 years: stood at $281.0 million in 2022, then plunged by 178.29% to -$220.0 million in 2023, then surged by 67.27% to -$72.0 million in 2024, then plunged by 148.61% to -$179.0 million in 2025, then rose by 25.14% to -$134.0 million in 2026.
- The last three Change in Receivables figures came in at -$134.0 million (Q1 2026), -$179.0 million (Q4 2025), and $333.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 1.35 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 1.37 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 1.09 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 333.00 Mn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | - |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 333.00 Mn |
| Jun 30, 2026 | 333.00 Mn |
| Mar 31, 2026 | -134.00 Mn |
| Mar 31, 2026 | -134.00 Mn |
| Dec 31, 2025 | -179.00 Mn |
| Dec 31, 2025 | -179.00 Mn |
| Sep 30, 2025 | 333.00 Mn |
| Sep 30, 2025 | 333.00 Mn |
| Jun 30, 2025 | 292.00 Mn |
| Jun 30, 2025 | 292.00 Mn |
| Mar 31, 2025 | -79.00 Mn |
| Mar 31, 2025 | -79.00 Mn |
| Dec 31, 2024 | -72.00 Mn |
| Dec 31, 2024 | -72.00 Mn |
| Sep 30, 2024 | -162.00 Mn |
| Sep 30, 2024 | -162.00 Mn |
| Jun 30, 2024 | 29.00 Mn |
| Jun 30, 2024 | 29.00 Mn |
| Mar 31, 2024 | 66.00 Mn |
| Mar 31, 2024 | 66.00 Mn |